BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
+17.68%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$149M
AUM Growth
+$149M
(+18%)
Cap. Flow
-$69.4M
Cap. Flow
% of AUM
-46.47%
Top 10 Holdings %
Top 10 Hldgs %
80.92%
Holding
38
New
3
Increased
10
Reduced
7
Closed
4
Top Buys
| 1 |
Aclaris Therapeutics
ACRS
|
$10.8M |
| 2 |
Instil Bio
TIL
|
$3.77M |
| 3 |
PMV Pharmaceuticals
PMVP
|
$2.22M |
| 4 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$1.43M |
| 5 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$1.22M |
Top Sells
| 1 |
Adverum Biotechnologies
ADVM
|
$52.6M |
| 2 |
Q32 Bio
QTTB
|
$12.3M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
$8.56M |
| 4 |
Tourmaline Bio
TRML
|
$6.43M |
| 5 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$4.49M |
Sector Composition
| 1 | Healthcare | 68.18% |
| 2 | Technology | 1.32% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$56.1B
| $27.2M | 17.93% | 270,000 | – | – |
|
2
Atea Pharmaceuticals
AVIR
$267M
| $22.4M | 14.75% | 5,536,710 +74,631 | +1% | +$302K |
|
3
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $18.4M | 12.11% | 200,000 | – | – |
|
|
4
Adverum Biotechnologies
ADVM
$64.6M
| $11.8M | 7.77% | 833,117 -3,721,135 | -82% | -$52.6M |
|
|
5
Aclaris Therapeutics
ACRS
$209M
| $11.7M | 7.68% | 9,395,934 +8,742,827 | +1,339% | +$10.8M |
|
|
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $11M | 7.25% | 3,654,053 +404,045 | +12% | +$1.22M |
|
|
CLYM
7
Climb Bio, Inc. Common Stock
CLYM
$151M
| $6.01M | 3.96% | 2,193,742 +13,742 | +0.6% | +$37.7K |
|
|
TECX
8
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $5.12M | 3.38% | 4,001,627 | – | – |
|
|
9
Instil Bio
TIL
$182M
| $3.77M | 2.48% | +348,735 | New | +$3.77M |
|
|
OKUR
10
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $3.62M | 2.38% | 2,177,913 +863,684 | +66% | +$1.43M |
|
|
CNTB
11
Connect Biopharma
CNTB
$115M
| $3.59M | 2.37% | 2,061,338 -100 | -0% | -$174 |
|
12
Design Therapeutics
DSGN
$315M
| $3.54M | 2.34% | 879,478 -150,000 | -15% | -$605K |
|
13
Athira Pharma
ATHA
$15.3M
| $2.47M | 1.63% | 900,000 -554,362 | -38% | -$1.52M |
|
14
Oramed Pharmaceuticals
ORMP
$90.2M
| $2.47M | 1.63% | 844,496 -417,063 | -33% | -$1.22M |
|
|
15
PMV Pharmaceuticals
PMVP
$74.2M
| $2.22M | 1.46% | +1,306,490 | New | +$2.22M |
|
16
Astrotech Corp
ASTC
$8.72M
| $1.97M | 1.3% | 220,410 | – | – |
|
|
LENZ
17
LENZ Therapeutics
LENZ
$1.1B
| $1.43M | 0.94% | 63,916 -383,500 | -86% | -$8.56M |
|
|
KNTE
18
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $1.33M | 0.88% | 498,851 +30,641 | +7% | +$81.5K |
|
|
ORKA
19
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.24M | 0.82% | 706,930 | – | – |
|
20
Forte Biosciences
FBRX
$137M
| $1.23M | 0.81% | 1,761,702 | – | – |
|
21
Milestone Pharmaceuticals
MIST
$156M
| $1.09M | 0.72% | 606,145 +163,793 | +37% | +$293K |
|
22
Verrica Pharmaceuticals
VRCA
$52.8M
| $1.07M | 0.7% | 180,000 | – | – |
|
23
Lisata Therapeutics
LSTA
$19.9M
| $888K | 0.59% | 284,669 +14,830 | +5% | +$46.3K |
|
24
Enliven Therapeutics
ELVN
$1.2B
| $881K | 0.58% | 50,100 +100 | +0.2% | +$1.76K |
|
25
VistaGen Therapeutics
VTGN
$102M
| $792K | 0.52% | 150,000 | – | – |
|